Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 716

The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.

Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis

Open access
Busse, Jason W., Wang, Li, Kamaleldin, Mostafa, Craigie, Samantha, Riva, John J., Montoya, Luis, Mulla, Sohail M., Lopes, Luciane C., Vogel, Nicole, Chen, Eric, Kirmayr, Karin, De Oliveira, Kyle, Olivieri, Lori, Kaushal, Alka, Chaparro, Luis E., Oyberman, Inna, Agarwal, Arnav, Couban, Rachel, Tsoi, Ludwig, Lam, Tommy, Vandvik, Per Olav, Hsu, Sandy, Bala, Malgorzata M., Schandelmaier, Stefan, Scheidecker, Anne, Ebrahim, Shanil, Ashoorion, Vahid, Rehman, Yasir, Hong, Patrick J., Ross, Stephanie, Johnston, Bradley C., Kunz, Regina, Sun, Xin, Buckley, Norman, Sessler, Daniel I., Guyatt, Gordon H. · 2018 · JAMA

Abstract

Importance: Harms and benefits of opioids for chronic noncancer pain remain unclear. Objective: To systematically review randomized clinical trials (RCTs) of opioids for chronic noncancer pain. Data Sources and Study Selection: The databases of CENTRAL, CINAHL, EMBASE, MEDLINE, AMED, and PsycINFO were searched from inception to April 2018 for RCTs of opioids for chronic noncancer pain vs any nonopioid control. Data Extraction and Synthesis: Paired reviewers independently extracted data. The analyses used random-effects models and the Grading of Recommendations Assessment, Development and Evaluation to rate the quality of the evidence. Main Outcomes and Measures: The primary outcomes were pain intensity (score range, 0-10 cm on a visual analog scale for pain; lower is better and the minimally important difference [MID] is 1 cm), physical functioning (score range, 0-100 points on the 36-item Short Form physical component score [SF-36 PCS]; higher is better and the MID is 5 points), and incidence of vomiting. Results: Ninety-six RCTs including 26 169 participants (61% female; median age, 58 years [interquartile range, 51-61 years]) were included. Of the included studies, there were 25 trials of neuropathic pain, 32 trials of nociceptive pain, 33 trials of central sensitization (pain present in the absence of tissue damage), and 6 trials of mixed types of pain. Compared with placebo, opioid use was associated with reduced pain (weighted mean difference [WMD], -0.69 cm [95% CI, -0.82 to -0.56 cm] on a 10-cm visual analog scale for pain; modeled risk difference for achieving the MID, 11.9% [95% CI, 9.7% to 14.1%]), improved physical functioning (WMD, 2.04 points [95% CI, 1.41 to 2.68 points] on the 100-point SF-36 PCS; modeled risk difference for achieving the MID, 8.5% [95% CI, 5.9% to 11.2%]), and increased vomiting (5.9% with opioids vs 2.3% with placebo for trials that excluded patients with adverse events during a run-in period). Low- to moderate-quality evidence suggested similar associations of opioids with improvements in pain and physical functioning compared with nonsteroidal anti-inflammatory drugs (pain: WMD, -0.60 cm [95% CI, -1.54 to 0.34 cm]; physical functioning: WMD, -0.90 points [95% CI, -2.69 to 0.89 points]), tricyclic antidepressants (pain: WMD, -0.13 cm [95% CI, -0.99 to 0.74 cm]; physical functioning: WMD, -5.31 points [95% CI, -13.77 to 3.14 points]), and anticonvulsants (pain: WMD, -0.90 cm [95% CI, -1.65 to -0.14 cm]; physical functioning: WMD, 0.45 points [95% CI, -5.77 to 6.66 points]). Conclusions and Relevance: In this meta-analysis of RCTs of patients with chronic noncancer pain, evidence from high-quality studies showed that opioid use was associated with statistically significant but small improvements in pain and physical functioning, and increased risk of vomiting compared with placebo. Comparisons of opioids with nonopioid alternatives suggested that the benefit for pain and functioning may be similar, although the evidence was from studies of only low to moderate quality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2018.18472

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 7

  1. Ward, 2014, Clinically important changes in Short Form 36 health survey scales for use in rheumatoid arthritis clinical trials., Arthritis Care Res (Hoboken), 66, 1783, 10.1002/acr.v66.12 · doi:10.1002/acr.v66.12
  2. Caldwell, 1999, Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs., J Rheumatol, 26, 862
  3. Emkey, 2004, Efficacy and safety of tramadol/acetaminophen tablets (ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug., J Rheumatol, 31, 150
  4. Mayorga, 2016, Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis., Int J Clin Pract, 70, 493, 10.1111/ijcp.2016.70.issue-6 · doi:10.1111/ijcp.2016.70.issue-6
  5. Peloso, 2004, Analgesic efficacy and safety of tramadol/acetaminophen combination tablets (ultracet) in treatment of chronic low back pain., J Rheumatol, 31, 2454
  6. Rauck, 2015, A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment., Pain, 156, 1660, 10.1097/j.pain.0000000000000230 · doi:10.1097/j.pain.0000000000000230
  7. Moran, 1991, MST continus tablets and pain control in severe rheumatoid arthritis., Br J Clin Res, 2, 1

Cited by

See all 716

Metadata

Authors
Busse, J. W., Wang, L., Kamaleldin, M., Craigie, S., Riva, J. J., Montoya, L., Mulla, S. M., Lopes, L. C., Vogel, N., Chen, E., Kirmayr, K., De Oliveira, K., Olivieri, L., Kaushal, A., Chaparro, L. E., Oyberman, I., Agarwal, A., Couban, R., Tsoi, L., Lam, T., Vandvik, P. O., Hsu, S., Bala, M. M., Schandelmaier, S., Scheidecker, A., Ebrahim, S., Ashoorion, V., Rehman, Y., Hong, P. J., Ross, S., Johnston, B. C., Kunz, R., Sun, X., Buckley, N., Sessler, D. I., & Guyatt, G. H.
Venue
JAMA
Published
2018-12-18
Volume
320
Issue
23
Pages
2448
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2904363872
Cited by
716
References
116
FWCI
62.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.